Skip to main content

Okey Stephanie's Form 4 filing

Crinetics Pharmaceuticals, Inc. (CRNX) · filed Jun 18, 2026

Accession no.
0001628280-26-044419
Filed
Jun 18, 2026
Trade date
Jun 17, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions. Open-market sales total $246.1K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Okey StephanieCIK 0001742616Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 17, 2026Common StockSSaleDisposed−6,292$35.62F2−$224,121.047,008Direct
Jun 17, 2026Common StockSSaleDisposed−608$36.22F3−$22,021.766,400Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $35.62 per share. The range of sale prices on the transaction date was $35.19 to $36.06. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F3

The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $36.22 per share. The range of sale prices on the transaction date was $36.19 to $36.29. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)